

CLIENT'S NAME AND ADDRESS:

CLIENT S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI
NEW DELHI 110030

DELHI INDIA 8800465156

SRL Ltd S.K. Tower,Hari Niwas, LBS Marg

THANE, 400602

MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: DIPALI AJIT DALVI

PATIENT ID:

DIPAF300387181

ACCESSION NO: 0181VK000551 AGE: 35 Years SEX: Female

ABHA NO:

DRAWN:

RECEIVED: 12/11/2022 09:03:52

REPORTED: 16/11/2022 11:23:46

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results		Biological Referenc	e Interval Units
MEDI WHEEL FULL BODY HEALTH CHECKUP	BELOW 40FEMALE			
BLOOD COUNTS,EDTA WHOLE BLOOD				
HEMOGLOBIN (HB)	14.3		12.0 - 15.0	g/dL
METHOD: SLS-HEMOGLOBIN DETECTION METHOD				5.
RED BLOOD CELL (RBC) COUNT	5.97	High	3.8 - 4.8	mil/μL
METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION				
WHITE BLOOD CELL (WBC) COUNT	6.20		4.0 - 10.0	thou/µL
METHOD: FLUORESCENCE FLOW CYTOMETRY				
PLATELET COUNT	350		150 - 410	thou/µL
METHOD: HYDROD YNAMIC FOCUSING BY DC DETECTION				
RBC AND PLATELET INDICES				
HEMATOCRIT (PCV)	43.9		36.0 - 46.0	%
METHOD: CUMULATIVE PULSE HEIGHT DETECTION METHOD				
MEAN CORPUSCULAR VOLUME (MCV)	73.5	Low	83.0 - 101.0	fL
METHOD: CALCULATED FROM RBC & HCT				
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	24.0	Low	27.0 - 32.0	pg
METHOD: CALCULATED FROM THE RBC & HGB				
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD: CALCULATED FROM THE HGB & HCT	32.6		31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW)	14.0		11.6 - 14.0	%
METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVI				
MENTZER INDEX	12.3			
MEAN PLATELET VOLUME (MPV)	9.7		6.8 - 10.9	fL
METHOD: CALCULATED FROM PLATELET COUNT & PLATELET H	EMATOCRIT			
WBC DIFFERENTIAL COUNT				
NEUTROPHILS	52		40 - 80	%
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING				
LYMPHOCYTES	41	High	20 - 40	%
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING				
MONOCYTES	6		2 - 10	%
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING				
EOSINOPHILS	1		1 - 6	%
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING				
ABSOLUTE NEUTROPHIL COUNT	3.24		2.0 - 7.0	thou/µL
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING				



Page 1 Of 14 Scan to View Report



CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDI WHEEL)
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI
NEW DELHI 110030

DELHI INDIA 8800465156

SRL Ltd S.K. Tower,Hari Niwas, LBS Marg

THANE, 400602

MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: DIPALI AJIT DALVI PATIENT ID : DIPAF300387181

ACCESSION NO: 0181VK000551 AGE: 35 Years SEX: Female ABHA NO:

RECEIVED: 12/11/2022 09:03:52 REPORTED: 16/11/2022 11:23:46 DRAWN:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status	Final	Results	Biological Reference Interva	l Units
ABSOLUTE LYMPHOCYT	TE COUNT	2.53	1.0 - 3.0	thou/µL
METHOD : FLOW CYTOMETR	Y WITH LIGHT SCATTERING			
ABSOLUTE MONOCYTE		0.35	0.2 - 1.0	thou/µL
METHOD : FLOW CYTOMETR	Y WITH LIGHT SCATTERING			
ABSOLUTE EOSINOPHI		0.05	0.02 - 0.50	thou/µL
METHOD : FLOW CYTOMETR				
NEUTROPHIL LYMPHOC	CYTE RATIO (NLR)	1.3		
MORPHOLOGY				
RBC		NORMOCYTIC NORMOCHRO	DMIC	
WBC		NORMAL MORPHOLOGY		
METHOD : MICROSCOPIC EX	(ΑΜΙΝΑΠΟΝ			
PLATELETS		ADEQUATE		
ERYTHROCYTE SEDII	MENTATION RATE (ESR),WI	HOLE		
E.S.R		08	0 - 20	mm at 1 hr
METHOD : WESTERGREN ME	THOD			
GLUCOSE FASTING,F	LUORIDE PLASMA			
FBS (FASTING BLOOD	SUGAR)	84	Normal 75 - 99 Pre-diabetics: 100 - 125 Diabetic: > or = 126	mg/dL
METHOD: ENZYMATIC REFE	RENCE METHOD WITH HEXOKINASE			
	OGLOBIN(HBA1C), EDTA W	HOLE		
BLOOD HBA1C		5.2	Non-diabetic Adult < 5.7	%
		3.2	Pre-diabetes 5.7 - 6.4 Diabetes diagnosis: > or = 6.5 Therapeutic goals: < 7.0 Action suggested: > 8.0 (ADA Guideline 2021)	90
METHOD : HPLC	CHICOGE(EAC)	100 E	< 116.0	ma/dl
ESTIMATED AVERAGE	• ,	102.5	< 116.0	mg/dL
METHOD : CALCULATED PAR				
GLUCOSE, POST-PRA	•	00	70 400	
PPBS(POST PRANDIAL	•	80	70 - 139	mg/dL
METHOD: ENZYMATIC REFE	RENCE METHOD WITH HEXOKINASE			

LIPID PROFILE, SERUM



Page 2 Of 14 Scan to View Report



CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDI WHEEL)
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI
NEW DELHI 110030

DELHI INDIA 8800465156

SRL Ltd S.K. Tower,Hari Niwas, LBS Marg

THANE, 400602

MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: DIPALI AJIT DALVI

PATIENT ID: DIPAF300387181

ACCESSION NO: 0181VK000551 AGE: 35 Years SEX: Female ABHA NO:

RECEIVED: 12/11/2022 09:03:52 REPORTED: 16/11/2022 11:23:46 DRAWN:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results		Biological Reference Interv	al Units
CHOLESTEROL, TOTAL	211	High	Desirable cholesterol level < 200 Borderline high cholesterol 200 - 239 High cholesterol > / = 240	mg/dL
METHOD: ENZYMATIC COLORIMETRIC ASSAY TRIGLYCERIDES METHOD: ENZYMATIC COLORIMETRIC ASSAY	150		Normal: < 150 Borderline high: 150 - 199 High: 200 - 499 Very High: >/= 500	mg/dL
HDL CHOLESTEROL	41		Low HDL Cholesterol <40 High HDL Cholesterol >/= 60	mg/dL
METHOD: ENZYMATIC, COLORIMETRIC CHOLESTEROL LDL	140	High	Adult levels: Optimal < 100 Near optimal/above optimal: 1 129 Borderline high: 130-159 High: 160-189 Very high: = 190	mg/dL 00-
METHOD: ENZYMATIC COLORIMETRIC ASSAY NON HDL CHOLESTEROL	170	High	Desirable : < 130 Above Desirable : 130 -159 Borderline High : 160 - 189 High : 190 - 219 Very high : > / = 220	mg/dL
CHOL/HDL RATIO	5.2	High	Low Risk: 3.3 - 4.4 Average Risk: 4.5 - 7.0 Moderate Risk: 7.1 - 11.0 High Risk: > 11.0	
LDL/HDL RATIO	3.4	High	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate >6.0 High Risk	Risk
VERY LOW DENSITY LIPOPROTEIN LIVER FUNCTION PROFILE, SERUM	30.0		< OR = 30.0	mg/dL
BILIRUBIN, TOTAL METHOD: COLORIMETRIC DIAZO	0.63		Upto 1.2	mg/dL
BILIRUBIN, DIRECT BILIRUBIN, INDIRECT	0.24 0.39		< 0.30 0.1 - 1.0	mg/dL mg/dL







CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDI WHEEL)
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI
NEW DELHI 110030

DELHI INDIA 8800465156

SRL Ltd S.K. Tower,Hari Niwas, LBS Marg

THANE, 400602

MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: DIPALI AJIT DALVI

PATIENT ID : DIPAF300387181

ACCESSION NO: 0181VK000551 AGE: 35 Years SEX: Female ABHA NO:

RECEIVED: 12/11/2022 09:03:52 REPORTED: 16/11/2022 11:23:46 DRAWN:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results	Biological Reference I	Interval Units
TOTAL PROTEIN	7.5	6.0 - 8.0	g/dL
METHOD: COLORIMETRIC			
ALBUMIN METHOD: COLORIMETRIC	4.6	3.97 - 4.94	g/dL
GLOBULIN	2.9	2.0 - 3.5	g/dL
ALBUMIN/GLOBULIN RATIO	1.6	1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE (AST/SGOT) METHOD: UV ABSORBANCE	24	< OR = 35	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD: UV ABSORBANCE	35	< OR = 35	U/L
ALKALINE PHOSPHATASE METHOD: COLORIMETRIC	80	35 - 104	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD: ENZYMATIC, COLORIMETRIC	13	0 - 40	U/L
LACTATE DEHYDROGENASE	184	125 - 220	U/L
METHOD: UV ABSORBANCE			
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN	7	6 - 20	mg/dL
METHOD : ENZYMATIC ASSAY			
CREATININE, SERUM			
CREATININE	0.67	0.5 - 0.9	mg/dL
METHOD: COLORIMETRIC			
BUN/CREAT RATIO			
BUN/CREAT RATIO	10.45	8.0 - 15.0	
URIC ACID, SERUM			
URIC ACID	3.9	2.4 - 5.7	mg/dL
METHOD: ENZYMATIC COLORIMETRIC ASSAY			
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN	7.5	6.0 - 8.0	g/dL
METHOD: COLORIMETRIC			
ALBUMIN, SERUM			
ALBUMIN	4.6	3.97 - 4.94	g/dL
METHOD: COLORIMETRIC			
GLOBULIN			
GLOBULIN	2.9	2.0 - 3.5	g/dL







CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDI WHEEL)
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI
NEW DELHI 110030

DELHI INDIA 8800465156

SRL Ltd S.K. Tower,Hari Niwas, LBS Marg

THANE, 400602

MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: DIPALI AJIT DALVI

PATIENT ID: DIPAF300387181

ACCESSION NO: 0181VK000551 AGE: 35 Years SEX: Female ABHA NO:

RECEIVED: 12/11/2022 09:03:52 REPORTED: 16/11/2022 11:23:46 DRAWN:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

SODIUM, SERUM 138 136 - 145 mmol/L	Test Report Status <u>Final</u>	Results	Biological Reference Inter	val Units
SODIUM, SERUM	FLECTROLITES (NA /V/OL) CERUM			
POTASSIUM, SERUM CHLORIDE, SERUM D100 SPA = 107 MITHOPIPETATION(S) PHYSICAL EXAMINATION, URINE COLOR METHOD: VISUAL INSPECTION APPEARANCE METHOD: VISUAL INSPECTION APPEARANCE METHOD: VISUAL INSPECTION CHEMICAL EXAMINATION, URINE PH 6.0 METHOD: DOUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY METHOD: DOUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY METHOD: IDNIC CONCENTRATION METHOD PROTEIN METHOD: IDNIC CONCENTRATION METHOD PROTEIN METHOD: SETERA BROMOPHENOL BLUE/SULFOSALICYLLC ACID METHOD: GULCOSE OND DETECTED MOT DETECTED MOT DETECTED MOTO DETECTE		120	106 145	mana l / l
CHLORIDE, SERUM Interpretation(s) PHYSICAL EXAMINATION, URINE COLOR METHOD: YISUAL INSPECTION APPEARANCE METHOD: YISUAL INSPECTION APPEARANCE METHOD: YISUAL INSPECTION CHEMICAL EXAMINATION, URINE PH 6.0.4 METHOD: YISUAL INSPECTION CHEMICAL EXAMINATION, URINE PH 6.0.0 METHOD: OUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY 1.005 METHOD: IONIC CONCENTRATION METHOD PROTEIN METHOD: IONIC CONCENTRATION METHOD PROTEIN METHOD: SULUCOSE OND DETECTED NOT DETECTED NOT DETECTED NOT DETECTED MOT DETECTED NOT DETECTED MOT DETECT				
Theoretation(s) PHYSICAL EXAMINATION, URINE COLOR PALE YELLOW METHOC: VISUAL INSPECTION APPEARANCE METHOC: VISUAL INSPECTION CHEMICAL EXAMINATION, URINE CHEMICAL EXAMINATION, URINE CHEMICAL EXAMINATION, URINE PH 6.0 6.0 4.7 - 7.5 METHOC: DOUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY METHOC: SOUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY METHOC: SOUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY METHOC: SOUBLE INDICATOR PRINCIPLE SPECIFIC MACTION METHOC: SOUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY METHOC: SOUBLE INDICATOR PRINCIPLE SUCCOSE METHOC: SOUBLE SECONDASE METHOC: SULLOSE OND ASSE PEROXIDASE KETONES METHOC: MITROPRUSSIDE REACTION METHOC: MITROPRUSSIDE REACTION METHOC: MITROPRUSSIDE REACTION METHOC: MITROPRUSSIDE REACTION METHOC: MODIFIED EHRLICH REACTION MOT DETECTED MOT DETEC				
PHYSICAL EXAMINATION, URINE COLOR METHOD: VISUAL INSPECTION APPEARANCE METHOD: VISUAL INSPECTION CHEMICAL EXAMINATION, URINE PH 6.0 4.7 - 7.5 METHOD: DOUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY 1.005 1.003 1.003 1.003 METHOD: IONIC CONCENTRATION METHOD PROTEIN METHOD: IONIC CONCENTRATION METHOD #METHOD: SULUCOSE OND ASE PEROXIDASE KETONES METHOD: SULUCOSE OND ASE PEROXIDASE KETONES METHOD: NOT DETECTED NOT DETECTED METHOD: NOT DETECTED METHOD: NOT DETECTED METHOD: METHOD: MITHORPRUSSIDE REACTION METHOD: PREDXIDASE UROBILINOGEN METHOD: MORMAL MORMAL MORMAL METHOD: MORMAL MORM		100	98 - 107	mmol/L
COLOR METHOD: VISUAL INSPECTION APPERANCE METHOD: VISUAL INSPECTION CHEMICAL EXAMINATION, URINE PH 6.0.0 METHOD: DOUBLE INDICATOR PRINCIPLE SPECIFIC GRANITY METHOD: DOUBLE INDICATOR PRINCIPLE SPECIFIC GRANITY METHOD: IONIC CONCENTRATION METHOD METHOD: ITETRA BROMOPHENOL BLUE/SULFOSALICYLIC ACID METHOD: GLUCOSE OXIDASE PEROXIDASE KETONES METHOD: RUINFORUSSIDE REACTION METHOD: INTROPRUSSIDE REACTION METHOD: INTROPRUSSIDE REACTION METHOD: PROXIDASE UROBILINOGEN METHOD: PROXIDASE UROBILINOGEN METHOD: MORMAL METH	Interpretation(s)			
METHOD: VISUAL INSPECTION APPEARANCE METHOD: VISUAL INSPECTION CHEMICAL EXAMINATION, URINE PH METHOD: DOUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY METHOD: IONIC CONCENTRATION METHOD METHOD: IONIC CONCENTRATION METHOD METHOD: TETRA BROMOPHENOL BLUE/SULFOSALICYLIC ACID METHOD: ICUCOSE METHOD: RIVERORIA SEPEROXIDASE KETONES METHOD: INTROPRUSSIDE REACTION METHOD: NOT DETECTED METHOD: NITROPRUSSIDE REACTION METHOD: PEROXIDASE METHOD: PEROXIDASE NOT DETECTED METHOD: MODIFIED EHRLICH REACTION METHOD: MODIFIED EHRLICH REACTION NOT DETECTED NOT DETE	PHYSICAL EXAMINATION, URINE			
APPEARANCE METHOD: VISUAL INSPECTION CHEMICAL EXAMINATION, URINE PH 6.0 4.7 - 7.5 METHOD: DOUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY 1.005 1.005 1.003 1.003 1.005 METHOD: IONIC CONCENTRATION METHOD PROTEIN NOT DETECTED NOT DETECTED METHOD: ETERA BROMOPHENOL BLUE/SULFOSALICYLIC ACID METHOD: GLUCOSE OXIDASE PEROXIDASE KETONES NOT DETECTED NOT DETECTED METHOD: NITROPRUSSIDE REACTION METHOD: PEROXIDASE UROBILINOGEN NORMAL NORMAL METHOD: MODIFIED EHRLICH REACTION METHOD: MODIFIED EHRLICH REACTION NOT DETECTED NORMAL NOT DETECTED NOT DETECTED METHOD: 1,2,3,4-TETRAHYDROBENZO(H)QUINOLIN-3-OL LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED MICROSCOPIC EXAMINATION, URINE PUS CELL (WBC'S) OND DETECTED NOT DETECTED NOT DETECTED METHOD: MICROSCOPIC EXAMINATION PUS CELL (WBC'S) OND DETECTED NOT DETECTED NOT DETECTED METHOD: MICROSCOPIC EXAMINATION METHOD: MICROSCOPIC EXAMINATION	COLOR	PALE YELLOW		
METHOD: VISUAL INSPECTION CHEMICAL EXAMINATION, URINE PH 6.0 6.0 4.7 - 7.5 METHOD: DOUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY 1.005 1.003 - 1.003 - 1.035 METHOD: IONIC CONCENTRATION METHOD PROTEIN NOT DETECTED NOT DETECTED METHOD: TETRA BROMOPHENOL BLUE/SULFOSALICYLIC ACID METHOD: GLUCOSE OXIDASE PEROXIDASE KETONES NOT DETECTED NOT DETECTED METHOD: NITROPRUSSIDE REACTION METHOD: NITROPRUSSIDE REACTION METHOD: PEROXIDASE UROBILINOGEN NORMAL NORMAL METHOD: MODIFIED EHRLICH REACTION NOT DETECTED NOT DETECTED METHOD: MODIFIED EHRLICH REACTION NOT DETECTED NOT DETECTED METHOD: J.2,3,4-TETRAHYDROBENZO(H)QUINOLIN-9-OL LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED MICROSCOPIC EXAMINATION, URINE PUS CELL (WBC'S) NOT DETECTED NOT DETECTED NOT DETECTED /HPF METHOD: MICROSCOPIC EXAMINATION	METHOD: VISUAL INSPECTION			
CHEMICAL EXAMINATION, URINE PH 6.0 6.0 4.7 - 7.5 METHOD : DOUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY 1.005 1.005 1.003 - 1.035 METHOD : TONIC CONCENTRATION METHOD PROTEIN NOT DETECTED NOT DETECTED METHOD : TETRA BROMOPHENOL BLUE/SULFOSALICYLIC ACID GLUCOSE NOTD DETECTED NOT DETECTED METHOD : GLUCOSE OXIDASE PEROXIDASE KETOMES NOT DETECTED NOT DETECTED METHOD : NITROPRUSSIDE REACTION BLOOD NOT DETECTED NOT DETECTED METHOD : PROXIDASE UROBILINOGEN NORMAL NORMAL METHOD : MODIFIED EHRLICH REACTION NOT DETECTED NOT DETECTED METHOD : MODIFIED EHRLICH REACTION METHOD : 1,2,3,4-TETRAHYDROBENZO(H)QUINOLIN-3-OL LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED METHOD : L2,3,4-TETRAHYDROBENZO(H)QUINOLIN-3-OL RED BLOOD CELLS METHOD : MICROSCOPIC EXAMINATION PUS CELL (WBC'S) NOT DETECTED NOT DETECTED NOT DETECTED METHOD : MICROSCOPIC EXAMINATION PUS CELL (WBC'S) NOT DETECTED NOT DETECTED NOT DETECTED /HPF METHOD : MICROSCOPIC EXAMINATION	APPEARANCE	CLEAR		
PH METHOD: DOUBLE INDICATOR PRINCIPLE METHOD: DOUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY METHOD: IONIC CONCENTRATION METHOD METHOD: IONIC CONCENTRATION METHOD PROTEIN METHOD: TETRA BROMOPHENOL BLUE/SULFOSALICYLIC ACID METHOD: GLUCOSE OXIDASE PEROXIDASE KETONES METHOD: SULTROPRUSSIDE REACTION METHOD: NOT DETECTED METHOD: NOT DETECTED METHOD: PEROXIDASE UROBILLINOGEN METHOD: PEROXIDASE UROBILLINOGEN METHOD: 1,2,3,4-TETRAHYDROBENZO(H)QUINOLIN-3-OL ELUKOCYTE ESTERASE MICHOD: MICROSCOPIC EXAMINATION, URINE RED BLOOD CELLS METHOD: MICROSCOPIC EXAMINATION PUS CELL (WBC'S) METHOD: MICROSCOPIC EXAMINATION METHOD: MICROSCOPIC EXAMINATION PUS CELL (WBC'S) METHOD: MICROSCOPIC EXAMINATION	METHOD: VISUAL INSPECTION			
METHOD: DOUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY METHOD: IONIC CONCENTRATION METHOD PROTEIN METHOD: TETRA BROMOPHENOL BLUE/SULFOSALICYLIC ACID METHOD: TETRA BROMOPHENOL BLUE/SULFOSALICYLIC ACID METHOD: GLUCOSE METHOD: GLUCOSE OXIDASE PEROXIDASE KETONES METHOD: NITROPRUSSIDE REACTION BLOOD METHOD: NOT DETECTED MOT DETECT	CHEMICAL EXAMINATION, URINE			
SPECIFIC GRAVITY METHOD: IONIC CONCENTRATION METHOD PROTEIN METHOD: TETRA BROMOPHENOL BLUE/SULFOSALICYLIC ACID METHOD: TETRA BROMOPHENOL BLUE/SULFOSALICYLIC ACID METHOD: GLUCOSE METHOD: GLUCOSE OXIDASE PEROXIDASE KETONES METHOD: NITROPRUSSIDE REACTION METHOD: PROXIDASE UROBILINOGEN METHOD: PROXIDASE UROBILINOGEN METHOD: MODIFIED EHRLICH REACTION NOT DETECTED NOT DETECTED /HPF METHOD: MICROSCOPIC EXAMINATION	PH	6.0	4.7 - 7.5	
METHOD: IONIC CONCENTRATION METHOD PROTEIN METHOD: TETRA BROMOPHENOL BLUE/SULFOSALICYLIC ACID GLUCOSE METHOD: GLUCOSE OXIDASE PEROXIDASE KETONES METHOD: NITROPRUSSIDE REACTION BLOOD METHOD: PEROXIDASE UROBILINOGEN METHOD: MOT DETECTED METHOD: MOT DETECTED METHOD: MOT DETECTED METHOD: MOT DETECTED METHOD: MOT DETECTED /HPF METHOD: MICROSCOPIC EXAMINATION PUS CELL (WBC'S) MOT DETECTED O-5 /HPF	METHOD: DOUBLE INDICATOR PRINCIPLE			
PROTEIN METHOD: TETRA BROMOPHENOL BLUE/SULFOSALICYLIC ACID METHOD: GLUCOSE METHOD: GLUCOSE OXIDASE PEROXIDASE KETONES METHOD: NITROPRUSSIDE REACTION BLOOD METHOD: PEROXIDASE UROBILINOGEN METHOD: MODIFIED EHRLICH REACTION NOT DETECTED METHOD: 1,2,3,4-TETRAHYDROBENZO(H)QUINOLIN-3-OL LEUKOCYTE ESTERASE MICROSCOPIC EXAMINATION, URINE PUS CELL (WBC'S) METHOD: MICROSCOPIC EXAMINATION	SPECIFIC GRAVITY	1.005	1.003 - 1.035	
METHOD: TETRA BROMOPHENOL BLUE/SULFOSALICYLIC ACID GLUCOSE METHOD: GLUCOSE OXIDASE PEROXIDASE KETONES METHOD: NITROPRUSSIDE REACTION METHOD: PEROXIDASE LOROBLINOGEN METHOD: MODIFIED EHRLICH REACTION NOT DETECTED METHOD: 1,2,3,4-TETRAHYDROBENZO(H)QUINOLIN-3-OL LEUKOCYTE ESTERASE MICROSCOPIC EXAMINATION, URINE RED BLOOD CELLS METHOD: MICROSCOPIC EXAMINATION PUS CELL (WBC'S) METHOD: MICROSCOPIC EXAMINATION METHOD: MICROSCOPIC EXAMINATION NOT DETECTED METHOD: MICROSCOPIC EXAMINATION NOT DETECTED METHOD: MICROSCOPIC EXAMINATION METHOD: MICROSCOPIC EXAMINATION PUS CELL (WBC'S) METHOD: MICROSCOPIC EXAMINATION	METHOD: IONIC CONCENTRATION METHOD			
GLUCOSE METHOD: GLUCOSE OXIDASE PEROXIDASE KETONES METHOD: NITROPRUSSIDE REACTION BLOOD METHOD: PEROXIDASE UROBILINOGEN METHOD: MODIFIED EHRLICH REACTION NOT DETECTED METHOD: 1,2,3,4-TETRAHYDROBENZO(H)QUINOLIN-3-OL LEUKOCYTE ESTERASE MICROSCOPIC EXAMINATION, URINE RED BLOOD CELLS METHOD: MICROSCOPIC EXAMINATION PUS CELL (WBC'S) METHOD: MICROSCOPIC EXAMINATION METHOD: MICROSCOPIC EXAMINATION PUS CELL (WBC'S) METHOD: MICROSCOPIC EXAMINATION METHOD: MICROSCOPIC EXAMINATION PUS CELL (WBC'S) METHOD: MICROSCOPIC EXAMINATION	PROTEIN	NOT DETECTED	NOT DETECTED	
METHOD : GLUCOSE OXIDASE PEROXIDASE KETONES METHOD : NITROPRUSSIDE REACTION BLOOD METHOD : PEROXIDASE UROBILINOGEN METHOD : MODIFIED EHRLICH REACTION NOT DETECTED METHOD : 1,2,3,4-TETRAH YDROBENZO(H)QUINOLIN-3-OL LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED MICROSCOPIC EXAMINATION, URINE RED BLOOD CELLS METHOD : MICROSCOPIC EXAMINATION PUS CELL (WBC'S) METHOD : MICROSCOPIC EXAMINATION				
KETONES METHOD: NITROPRUSSIDE REACTION BLOOD METHOD: PEROXIDASE UROBILINOGEN METHOD: MODIFIED EHRLICH REACTION NOT DETECTED METHOD: MICROSCOPIC EXAMINATION, URINE PUS CELL (WBC'S) METHOD: MICROSCOPIC EXAMINATION METHOD: MICROSCOPIC EXAMINATION NOT DETECTED /HPF METHOD: MICROSCOPIC EXAMINATION		NOT DETECTED	NOT DETECTED	
METHOD: NITROPRUSSIDE REACTION BLOOD METHOD: PEROXIDASE UROBILINOGEN METHOD: MODIFIED EHRLICH REACTION NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED METHOD: 1,2,3,4-TETRAHYDROBENZO(H)QUINOLIN-3-OL LEUKOCYTE ESTERASE NOT DETECTED MICROSCOPIC EXAMINATION, URINE RED BLOOD CELLS METHOD: MICROSCOPIC EXAMINATION PUS CELL (WBC'S) METHOD: MICROSCOPIC EXAMINATION METHOD: MICROSCOPIC EXAMINATION PUS CELL (WBC'S) METHOD: MICROSCOPIC EXAMINATION		NOT DETERTED	WAT DETECTED	
BLOOD METHOD: PEROXIDASE UROBILINOGEN METHOD: MODIFIED EHRLICH REACTION NITRITE METHOD: 1,2,3,4-TETRAHYDROBENZO(H)QUINOLIN-3-OL LEUKOCYTE ESTERASE MICROSCOPIC EXAMINATION, URINE RED BLOOD CELLS METHOD: MICROSCOPIC EXAMINATION PUS CELL (WBC'S) METHOD: MICROSCOPIC EXAMINATION		NOT DETECTED	NOT DETECTED	
METHOD : PEROXIDASE UROBILINOGEN METHOD : MODIFIED EHRLICH REACTION NITRITE METHOD : 1,2,3,4-TETRAHYDROBENZO(H)QUINOLIN-3-OL LEUKOCYTE ESTERASE MICROSCOPIC EXAMINATION, URINE RED BLOOD CELLS METHOD : MICROSCOPIC EXAMINATION PUS CELL (WBC'S) METHOD : MICROSCOPIC EXAMINATION METHOD : MICROSCOPIC EXAMINATION PUS CELL (WBC'S) METHOD : MICROSCOPIC EXAMINATION		NOT DETECTED	NOT DETECTED	
UROBILINOGEN METHOD: MODIFIED EHRLICH REACTION NITRITE METHOD: 1,2,3,4-TETRAHYDROBENZO(H)QUINOLIN-3-OL LEUKOCYTE ESTERASE MICROSCOPIC EXAMINATION, URINE RED BLOOD CELLS METHOD: MICROSCOPIC EXAMINATION PUS CELL (WBC'S) METHOD: MICROSCOPIC EXAMINATION METHOD: MICROSCOPIC EXAMINATION METHOD: MICROSCOPIC EXAMINATION METHOD: MICROSCOPIC EXAMINATION		NOT DETECTED	NOT DETECTED	
METHOD: MODIFIED EHRLICH REACTION NITRITE METHOD: 1,2,3,4-TETRAHYDROBENZO(H)QUINOLIN-3-OL LEUKOCYTE ESTERASE MICROSCOPIC EXAMINATION, URINE RED BLOOD CELLS METHOD: MICROSCOPIC EXAMINATION PUS CELL (WBC'S) METHOD: MICROSCOPIC EXAMINATION METHOD: MICROSCOPIC EXAMINATION METHOD: MICROSCOPIC EXAMINATION METHOD: MICROSCOPIC EXAMINATION		NODMAL	NODMAL	
NITRITE METHOD: 1,2,3,4-TETRAHYDROBENZO(H)QUINOLIN-3-OL LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED NOT DETECTED MICROSCOPIC EXAMINATION, URINE RED BLOOD CELLS METHOD: MICROSCOPIC EXAMINATION PUS CELL (WBC'S) METHOD: MICROSCOPIC EXAMINATION NOT DETECTED /HPF		NORMAL	NORMAL	
METHOD: 1,2,3,4-TETRAHYDROBENZO(H)QUINOLIN-3-OL LEUKOCYTE ESTERASE MICROSCOPIC EXAMINATION, URINE RED BLOOD CELLS METHOD: MICROSCOPIC EXAMINATION PUS CELL (WBC'S) METHOD: MICROSCOPIC EXAMINATION METHOD: MICROSCOPIC EXAMINATION		NOT DETECTED	NOT DETECTED	
LEUKOCYTE ESTERASE MICROSCOPIC EXAMINATION, URINE RED BLOOD CELLS METHOD: MICROSCOPIC EXAMINATION PUS CELL (WBC'S) METHOD: MICROSCOPIC EXAMINATION O-1 O-5 /HPF		NOT DETECTED	NOT DETECTED	
MICROSCOPIC EXAMINATION, URINE RED BLOOD CELLS METHOD: MICROSCOPIC EXAMINATION PUS CELL (WBC'S) METHOD: MICROSCOPIC EXAMINATION O-1 O-5 /HPF	·	NOT DETECTED	NOT DETECTED	
RED BLOOD CELLS MOT DETECTED NOT DETECTED /HPF METHOD: MICROSCOPIC EXAMINATION PUS CELL (WBC'S) METHOD: MICROSCOPIC EXAMINATION O-1 O-5 /HPF				
METHOD: MICROSCOPIC EXAMINATION PUS CELL (WBC'S) 0-1 0-5 /HPF METHOD: MICROSCOPIC EXAMINATION		NOT DETECTED	NOT DETECTED	/HDE
PUS CELL (WBC'S) 0-1 0-5 /HPF METHOD: MICROSCOPIC EXAMINATION		MOT DETECTED	NOT DETECTED	,
METHOD: MICROSCOPIC EXAMINATION		0-1	0-5	/HPF
		J .	3 3	,
	EPITHELIAL CELLS	0-1	0-5	/HPF



Page 5 Of 14 Scan to View Report



CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDI WHEEL)
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI
NEW DELHI 110030

DELHI INDIA 8800465156

SRL Ltd S.K. Tower,Hari Niwas, LBS Marg

THANE, 400602

MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: DIPALI AJIT DALVI

PATIENT ID:

DIPAF300387181

ACCESSION NO: 0181VK000551 AGE: 35 Years SEX: Female ABHA NO:

RECEIVED: 12/11/2022 09:03:52 REPORTED: 16/11/2022 11:23:46 DRAWN:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results	Biological Reference I	nterval Units
METHOD: MICROSCOPIC EXAMINATION			
CASTS	NOT DETECTED		
METHOD: MICROSCOPIC EXAMINATION			
CRYSTALS	NOT DETECTED		
METHOD: MICROSCOPIC EXAMINATION			
BACTERIA	NOT DETECTED	NOT DETECTED	
METHOD: MICROSCOPIC EXAMINATION			
YEAST	NOT DETECTED	NOT DETECTED	
Interpretation(s)			
THYROID PANEL, SERUM			
T3	103.0	80 - 200	ng/dL
METHOD: ELECTROCHEMILUMINESCENCE			
T4	10.30	5.1 - 14.1	μg/dL
METHOD: ELECTROCHEMILUMINESCENCE			· -•
TSH (ULTRASENSITIVE) METHOD: ELECTROCHEMILUMINESCENCE	2.220	0.27 - 4.2	μIU/mL







CLIENT CODE: C000138394 CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDI WHEEL) F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

REPORTED:

PATIENT NAME: DIPALI AJIT DALVI

PATIENT ID:

DIPAF300387181

ACCESSION NO: 0181VK000551 AGE: 35 Years SEX · Female ABHA NO:

DRAWN:

RECEIVED 12/11/2022 09:03:52

CLIENT PATIENT ID:

REFERRING DOCTOR: SELF

Final

Results

Biological Reference Interval Units

16/11/2022 11:23:46

Interpretation(s)

Test Report Status

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSII levels are significantly clevated, while in secondary and tertiary hypothyroidism, TSII levels are low. owidetlparowidetlparBelow mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSII & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions	
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3) Post Thyroidectomy (4) Post Radio-Iodine treatment	
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid hormone replacement therapy (3) In cases of Autoimmune/Hashimoto thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical inflammation, drugs like amphetamines, lodine containing drug and dopamine antagonist e.g. domperidone and other physiological reasons.	
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism	
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre (3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 replacement therapy (7) First trimester of Pregnancy	
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism	
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor	
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism	
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness	
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies	

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

PAPANICOLAOU SMEAR

SNR TEST METHOD

METHOD: MICROSCOPIC EXAMINATION

STOOL: OVA & PARASITE

COLOUR SAMPLE NOT RECEIVED



Page 7 Of 14 Scan to View Report



CLIENT CODE: C000138394 CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDI WHEEL) F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: DIPALI AJIT DALVI PATIENT ID: DIPAF300387181

ACCESSION NO: 0181VK000551 AGE: 35 Years SEX: Female ABHA NO:

RECEIVED: 12/11/2022 09:03:52 16/11/2022 11:23:46 DRAWN: REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units <u>Final</u>

METHOD: VISUAL Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE B

METHOD: GEL COLUMN AGGLUTINATION METHOD.

RH TYPE POSITIVE

METHOD: GEL COLUMN AGGLUTINATION METHOD.

XRAY-CHEST

IMPRESSION NO ABNORMALITY DETECTED

TMT OR ECHO

TMT OR ECHO **NEGATIVE**

ECG

ECG WITHIN NORMAL LIMITS

MEDICAL HISTORY

RELEVANT PRESENT HISTORY NOT SIGNIFICANT RELEVANT PAST HISTORY NOT SIGNIFICANT

RELEVANT PERSONAL HISTORY

MARRIED / 1 CHILD / MIXED DIET / NO ALLERGIES / NO SMOKING / NO

ALCOHOL.

MENSTRUAL HISTORY (FOR FEMALES) REGULAR: - 30/2-3 DAY

LMP (FOR FEMALES) 08/11/2022 **OBSTETRIC HISTORY (FOR FEMALES)** 1 LSCS,A0,L1 LCB (FOR FEMALES) 11 YEARS BACK.

RELEVANT FAMILY HISTORY BOTH PARENTS :- DIABETES.

HISTORY OF MEDICATIONS NOT SIGNIFICANT

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS 1.52 mts WEIGHT IN KGS. 75 Kgs BMI 32 BMI & Weight Status as follows: kg/sqmts

Below 18.5: Underweight

18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

GENERAL EXAMINATION



Page 8 Of 14 Scan to View Report



CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDI WHEEL)
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI
NEW DELHI 110030

DELHI INDIA 8800465156

SRL Ltd S.K. Tower,Hari Niwas, LBS Marg

THANE, 400602

MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: DIPALI AJIT DALVI

PATIENT ID : DIPAF300387181

ACCESSION NO: 0181VK000551 AGE: 35 Years SEX: Female ABHA NO:

RECEIVED: 12/11/2022 09:03:52 REPORTED: 16/11/2022 11:23:46 DRAWN:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
MENTAL / EMOTIONAL STATE	NORMAL	
PHYSICAL ATTITUDE	NORMAL	
GENERAL APPEARANCE / NUTRITIONAL STATUS	OBESE	
BUILT / SKELETAL FRAMEWORK	AVERAGE	
FACIAL APPEARANCE	NORMAL	
SKIN	NORMAL	
UPPER LIMB	NORMAL	
LOWER LIMB	NORMAL	
NECK	NORMAL	
NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TENI	DER
THYROID GLAND	NOT ENLARGED	
CAROTID PULSATION	NORMAL	
TEMPERATURE	NORMAL	
PULSE	72/MIN.REGULAR, ALL P BRUIT	ERIPHERAL PULSES WELL FELT, NO CAROTID
RESPIRATORY RATE	NORMAL	
CARDIOVASCULAR SYSTEM		
ВР	140/90 MM HG (SUPINE)	mm/Hg
PERICARDIUM	NORMAL	
APEX BEAT	NORMAL	
HEART SOUNDS	NORMAL	
MURMURS	ABSENT	
RESPIRATORY SYSTEM		
SIZE AND SHAPE OF CHEST	NORMAL	
MOVEMENTS OF CHEST	SYMMETRICAL	
BREATH SOUNDS INTENSITY	NORMAL	
BREATH SOUNDS QUALITY	VESICULAR (NORMAL)	
ADDED SOUNDS	ABSENT	
PER ABDOMEN		
APPEARANCE	NORMAL	
VENOUS PROMINENCE	ABSENT	
LIVER	NOT PALPABLE	
CNIEN	NOT DALDADLE	

NOT PALPABLE



SPLEEN

Page 9 Of 14



CLIENT CODE: C000138394 CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030

DELHI INDIA 8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602

MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: DIPALI AJIT DALVI

PATIENT ID: DIPAF300387181

ACCESSION NO: 0181VK000551 AGE: 35 Years SEX: Female ABHA NO:

RECEIVED: 12/11/2022 09:03:52 REPORTED: 16/11/2022 11:23:46 DRAWN:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
HERNIA	ABSENT	
CENTRAL NERVOUS SYSTEM		
HIGHER FUNCTIONS	NORMAL	
CRANIAL NERVES	NORMAL	
CEREBELLAR FUNCTIONS	NORMAL	
SENSORY SYSTEM	NORMAL	
MOTOR SYSTEM	NORMAL	
REFLEXES	NORMAL	
MUSCULOSKELETAL SYSTEM		
SPINE	NORMAL	
JOINTS	NORMAL	
BASIC EYE EXAMINATION		
CONJUNCTIVA	NORMAL	
EYELIDS	NORMAL	
EYE MOVEMENTS	NORMAL	
CORNEA	NORMAL	
DISTANT VISION RIGHT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT	
DISTANT VISION LEFT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT	
NEAR VISION RIGHT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT	
NEAR VISION LEFT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT	
COLOUR VISION	NORMAL	
SUMMARY		
RELEVANT HISTORY	NOT SIGNIFICANT	
RELEVANT GP EXAMINATION FINDINGS	OBESE :- BMI 32	
REMARKS / RECOMMENDATIONS	ADVICE:- 1)WEIGHT LOSS -LOW FA FIBRE DIET.	T,LOW CALORIE, LOW CARBOHYDRATE, HIGH
	2)REGULAR EXERCISE.REG	GULAR WALK FOR 30-40 MIN DAILY.
	3)REPEAT LIPID PROFILE	AFTER 3 MONTHS OF DIET AND EXERCISE.

4) BP MONITORING FOR IF PERSISTENTLY HIGH, WILL REQUIRE FURTHER EVALUATION & TREATMENT.

5)ADD YOGA, PRANAYAM MEDITATION TO DAILY ROUTINE.







CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDI WHEEL)
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI
NEW DELHI 110030

DELHI INDIA 8800465156

SRL Ltd S.K. Tower,Hari Niwas, LBS Marg

THANE, 400602

MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: DIPALI AJIT DALVI

PATIENT ID: DIPAF300387181

ACCESSION NO: 0181VK000551 AGE: 35 Years SEX : Female ABHA NO:

RECEIVED: 12/11/2022 09:03:52 REPORTED: 16/11/2022 11:23:46 DRAWN:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units Final







CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHT 110030 DELHI INDIA 8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: DIPALI AJIT DALVI

ABHA NO 1

REPORTED:

DIPAF300387181

ACCESSION NO: 0181VK000551 AGE: 35 Years

SEX · Female

16/11/2022 11:23:46

DRAWN:

RECEIVED 12/11/2022 09:03:52

CLIENT PATIENT ID:

PATIENT ID:

Test Report Status

<u>Final</u>

Results

Biological Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ULTRASOUND ABDOMEN ULTRASOUND ABDOMEN

REFERRING DOCTOR: SELF

GRADE I FATTY LIVER

Interpretation(s)
BLOOD COUNTS,EDTA WHOLE BLOOD-

The cell morphology is well preserved for 24hrs. However after 24–48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-

Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with dinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-

The optimal threshold of 3.3 for NLR showed a prognostic possibility of dinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504. This ratio element is a calculated parameter and out of NABL scope. ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION:

Erythrocyte sedimentation rate (ESR), who cell be sold be sedimented to resemble the first brocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of dear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).
In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm/hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia
False Decreased: Poikilocytosis,(SickleCells,spherocytes),Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, salicylates)

REFERENCE:

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRÍPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in

Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases (e.g., galactosemia), Drugs-insulin, ethanol, propranolol; sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

Hypoglycemia is defined as a glucoseof < 50 mg/dL in men and < 40 mg/dL in women.

While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.



Page 12 Of 14 回認須惠



CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDI WHEEL) F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHT 110030 DELHI INDIA 8800465156

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: DIPALI AJIT DALVI

PATIENT ID:

DIPAF300387181

Test Report Status

ACCESSION NO: 0181VK000551 AGE: 35 Years

SEX · Female

ABHA NO 1 REPORTED:

16/11/2022 11:23:46

DRAWN:

RECEIVED 12/11/2022 09:03:52

CLIENT PATIENT ID:

REFERRING DOCTOR: SELF

Results

Biological Reference Interval Units

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

<u>Final</u>

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2.Diagnosing diabetes. 3.Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

2. eAG gives an evaluation of blood glucose levels for the last couple of months.

3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to:
I.Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
II. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

III. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results. IV. Interference of hemoglobinopathies in HbA1c estimation is seen in

a. Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
b. Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
c. HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycsuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

LIVER FUNCTION PROFILE

Elikubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal musde, kidneys, brain, and red blood cells, and it is commonly measured dinically as a marker for liver health. AST levels increase during chronic viral hepatitis, block age of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, musdes, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalada, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein in deficiency, Wilson's disease, Goff is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measu and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Hum an serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol,

Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract

- Blockage in the urinary tract
 Kidney problems, such as kidney damage or failure, infection, or reduced blood flow

- Loss of body fluid (dehydration)
 Muscle problems, such as breakdown of muscle fibers
 Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preedampsia)

Lower than normal level may be due to:

- Myasthenia Gravis
- Múscular dystrophy



Page 13 Of 14



CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDI WHEEL) F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: DIPALI AJIT DALVI

PATIENT ID:

DIPAF300387181

ACCESSION NO: 0181VK000551 AGE: 35 Years

Test Report Status

SEX · Female

ABHA NO 1

DRAWN:

RECEIVED: 12/11/2022 09:03:52

REPORTED:

16/11/2022 11:23:46

REFERRING DOCTOR: SELF

<u>Final</u>

Results

Biological Reference Interval

CLIENT PATIENT ID:

Units

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUMSerum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage),Burns,Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome,Protein-losing enteropathy etc.

ÁLBUMIN, SERUM-

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic dearance, malnutrition and wasting etc. ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-

Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

End Of Report

Please visit www.srlworld.com for related Test Information for this accession

Scan to View Details

Page 14 Of 14